Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 13, 2015 08:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed to Present Clinical Data and Biomarker Analysis for Tarextumab at the 2015 Gastrointestinal Cancer Symposium

REDWOOD CITY, Calif., Jan. 13, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or...
January 12, 2015 08:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Pre-Announces 2014 Year-End Cash Balance and Provides 2015 Guidance

Begins 2015 with $232 Million in Cash Potential Milestones from Existing Partnerships in 2015/2016 Projected at Over $150 Million REDWOOD CITY, Calif., Jan. 12, 2015 (GLOBE NEWSWIRE) --...
January 07, 2015 08:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference

REDWOOD CITY, Calif., Jan. 7, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or...
January 05, 2015 08:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Doses First Patient in Phase 1 Clinical Trial of Novel Anti-DLL4/VEGF Bispecific Antibody

REDWOOD CITY, Calif., Jan. 5, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or...
December 01, 2014 08:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Begins Patient Dosing in Phase 2 Clinical Trial of Tarextumab (Anti-Notch 2/3, OMP-59R5) in Small Cell Lung Cancer

REDWOOD CITY, Calif., Dec. 1, 2014 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or...
November 21, 2014 08:00 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Presents New Clinical and Biomarker Data From Its Tarextumab and Demcizumab Clinical Trials at the EORTC-NCI-AACR Symposium

Biomarker Studies Demonstrate On-Target Effects of Tarextumab Against Notch Pathway and Cancer Stem Cells in Patients With Pancreatic Cancer Patient-Derived Preclinical and Clinical Data Support...
November 20, 2014 16:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Pharmaceuticals to Present at Piper Jaffray Healthcare Conference

REDWOOD CITY, Calif., Nov. 20, 2014 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or...
November 19, 2014 07:50 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Presents Biomarker-Focused Clinical Data From Phase 1a Trial of Anti-Notch1 (OMP-52M51) in Oral Plenary Session at the 26th EORTC-NCI-AACR Symposium

BARCELONA, Spain and REDWOOD CITY, Calif., Nov. 19, 2014 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem...
November 04, 2014 16:02 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Pharmaceuticals Announces Third Quarter 2014 Financial and Operating Results

Raises Year-End Cash Balance Guidance to Over $225 Million From $215 Million Management to Host Call at 4:30 pm ET to Discuss Quarter and Pipeline Advances REDWOOD CITY, Calif., Nov. 4, 2014...
November 03, 2014 08:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Pharmaceuticals Granted Anti-DLL4/Anti-VEGF Bispecific Antibody Patent in the U.S.

REDWOOD CITY, Calif., Nov. 3, 2014 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or...